Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology therapeutic agent.

Abstract: A gas turbine engine fuel supply system can include a fuel delivery system, a thermal management system, a fuel manifold, and one or more sensors that identify one or more fuel parameters. A fuel control system is provided that adjusts parameters of the fuel based on data received from the sensors.

Abstract: Described herein are hybrid adaptive networks (HAN) that enable the use of multiple, independent communications networks as a unified communications system. The disclosed HAN includes multiple communications networks that user terminals can simultaneously access. The disclosed HAN enables a user terminal to seamlessly roam across multiple communications networks. The disclosed HAN can increase the capabilities and resilience of user terminals by providing simultaneous access to multiple communications networks. For example, these communications networks may span multiple orbital regions, operate over multiple frequency bands, provide independent terrestrial infrastructure, and/or feature different network management and cyber defense implementations thereby providing inherent diversity and removing single points of failure and/or targets for attack.

Abstract: An immersion tank system includes an outer frame and an immersion tank disposed within the outer frame. A method for operating an immersion tank system includes inserting a payload into an immersion tank, flowing a source fluid from an external environment through tubing coupled to the immersion tank to a heat exchanger, cooling a working fluid using the heat exchanger and the source fluid, flowing the working fluid through one or more ports of the immersion tank, filling the immersion tank comprising the payload via the one or more ports to a predetermined level with the working fluid, transferring heat from the payload to the working fluid, exhausting gas and/or liquid from one or more vents defining a top surface of the immersion tank, and engaging one or more variable speed pumps for flowing the working fluid to the heat.

Abstract: This disclosure relates to methods for detecting a level of expression of one or more genes (or proteins) in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist, to treat the cancer.

Abstract: A system and method for labeling lids for utility access boxes using a receiver cast into the lid where the receiver has receiving slots with snap tabs for receiving cantilever arms on a name plate to affix the nameplate to the lid of the utility access box. Alternatively, receiving slots with snap tabs can be integrated in the lid for receiving cantilever arms on a nameplate to affix the nameplate to the lid of the utility access box without the need for a separate receiver.

Abstract: This disclosure relates to methods for detecting a level of expression of one or more genes in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist in combination with a PD-1 inhibitor and/or a PD-L 1 inhibitor, to treat the cancer.

Abstract: Generating an optimized supplier allocation plan includes identifying parts and suppliers associated with an allocation problem, where each supplier can supply at least one part. One or more objective functions are selected. Each objective function has part variables, and each part variable represents a quantity of a part to be procured from a supplier. At least one constraint constraining at least one part variable is received. The one or more objective functions are optimized with respect to the at least one constraint to yield a value for each part variable. A quantity of each part to be procured from at least one supplier is determined according to the values to generate the optimized supplier allocation plan.

Abstract: Provided herein are, inter alia, methods for treating oncovirus-positive cancers using anti-CD73 compounds, such as anti-CD73 antibodies. Exemplary oncovirus include human papilloma virus, hepatitis, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, human herpes virus-8, polyomavirus, adenovirus, human T-cell leukemia virus, and the like.

Abstract: Extrusion dies and methods of manufacturing extrusions dies, the extrusion die including a first plate and a second plate. The first plate has first upstream and downstream surfaces. A first material of the first plate has a first elastic modulus. The first plate includes pins formed between a plurality of slots. The pins and slots define a discharge face for the extrusion die at the first downstream surface of the first plate. The second plate has second upstream and downstream surfaces. The second plate is joined at the second downstream surface to the first upstream surface of the first plate. A second material of the second plate has a second elastic modulus. The second elastic modulus is greater than the first elastic modulus. A plurality of feed holes extend from the second upstream surface of the second plate through the extrusion die into communication with the slots.

Abstract: The anti-CD73 antibodies, compositions, and methods provided herein allow, inter alia, for the treatment of cancer and infectious diseases (e.g., bacterial, viral, fungal, parasitic), and for the generation of antigen-specific antibodies in vivo in a subject. Applicants have surprisingly found that administration of an anti-CD73 antibody (e.g., CPI-006) to a subject induces differentiation of B cells and robust expansion of specific B cell clones in the subject. The methods and compositions provided herein are, inter alia, useful for a variety of applications, including personalized medicine.

Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.

Abstract: Methods of manufacturing honeycomb-structure-forming extrusion dies having a number of slots for use in producing extruded articles having complex honeycomb patterns and extrusion dies for use in the manufacture of extruded honeycomb bodies. The method includes inserting a die insert having a runner and a number of teeth into a slot of an extrusion die such that each of the teeth blocks at least a portion of the slot of the extrusion die. The method further includes separating the runner from the teeth so that the teeth remain within the slot of the extrusion die.

Abstract: The present invention relates to a sugar paste substrate with a reduced sugar content comprising fondant, fructooligosaccharides (oligofructose or oligofructan) and starch. The paste can be used in standard sugar paste substrate processes, for example to produce printed decorations.

Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.

Abstract: Extrusion dies and methods of manufacturing extrusions dies, the extrusion die including a first plate and a second plate. The first plate has first upstream and downstream surfaces. A first material of the first plate has a first elastic modulus. The first plate includes pins formed between a plurality of slots. The pins and slots define a discharge face for the extrusion die at the first downstream surface of the first plate. The second plate has second upstream and downstream surfaces. The second plate is joined at the second downstream surface to the first upstream surface of the first plate. A second material of the second plate has a second elastic modulus. The second elastic modulus is greater than the first elastic modulus. A plurality of feed holes extend from the second upstream surface of the second plate through the extrusion die into communication with the slots.

Abstract: A honeycomb body having a honeycomb structure and a peripheral skin, the honeycomb structure having walls defining a plurality of cells including peripheral cells disposed directly adjacent to the peripheral skin. One or more of the peripheral cells is at least partially defined by a first wall surface, a second wall surface, and a skin surface portion extending between the first wall surface and the second wall surface. A continuously-varying radius extends from a first tangent to the first wall surface along the skin surface portion and to a second tangent to the second wall surface. Other honeycomb bodies, structures, and extrusion dies for forming honeycomb structures are disclosed.

Abstract: Methods for forming an electrode for use in forming a honeycomb extrusion die. The method includes forming, by means of an additive manufacturing process, an electrode includes a base having a web extending from the base. The web defines a matrix of cellular openings. The method further includes forming a secondary electrode having a plurality of pins. The plurality of pins are shaped and arranged so as to mate with the matrix of cellular openings defined by the web of the electrode. The method further includes machining the electrode using the secondary electrode to smooth surfaces of the electrode formed by the additive manufacturing process.

Abstract: A coated ceramic honeycomb body comprising a honeycomb structure comprising a matrix of intersecting porous walls forming a plurality of axially-extending channels, at least some of the plurality of axially-extending channels being plugged to form inlet channels and outlet channels, wherein a total surface area of the outlet channels is greater than a total surface area of the inlet channels, and wherein a catalyst is preferentially located within the outlet channels. and preferentially disposed on non-filtration walls of the outlet channels. Methods and apparatus configured to preferentially apply a catalyst-containing slurry to the outlet channels and non-filtration walls are provided, as are other aspects.

Abstract: A honeycomb body (300) including a plurality of radially-extending walls (322) intersecting with a plurality of circumferentially-extending walls (324), the plurality of radially-extending walls (322) and the plurality of circumferentially-extending walls (324) form a plurality of circumferential zones (334A, 334B, 334C) of cells (308). The plurality of circumferential zones (334A, 334B, 334C) of cells (308) includes a first zone of cells (334A) including two or more first rings of cells (330) and having a first cell density, and a second zone of cells (334B) including two or more rings of cells (330) having varying cell densities across the two or more rings of cells. Other structures and extrusion dies are disclosed.